MARKET

CAPR

CAPR

Capricor Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.820
+0.210
+5.82%
Opening 12:44 07/07 EDT
OPEN
3.620
PREV CLOSE
3.610
HIGH
3.848
LOW
3.618
VOLUME
29.52K
TURNOVER
80.46K
52 WEEK HIGH
5.85
52 WEEK LOW
2.560
MARKET CAP
92.92M
P/E (TTM)
-3.9954
1D
5D
1M
3M
1Y
5Y
Capricor posts statistically significant data for DMD candidate in open-label trial
Capricor Therapeutics (NASDAQ:CAPR) announced one-year results from a mid-stage open-label extension study on Monday to indicate that its lead asset CAP-1002 led to statistically significant clinical benefits in non-ambulant patients
Seekingalpha · 06/27 12:44
BRIEF-Capricor Therapeutics Announces Statistically Significant Clinical Benefits In Skeletal Muscle Function In Non-Ambulant Duchenne Muscular Dystrophy Patients Treated With Cap-1002 In Hope-2 Open Label Extension Study
BRIEF-Capricor Therapeutics Announces Statistically Significant Clinical Benefits In Skeletal Muscle Function In Non-Ambulant Duchenne Muscular Dystrophy Patients Treated With Cap-1002 In Hope-2 Open Label Extension Study
Reuters · 06/27 11:07
Capricor Therapeutics Announces Statistically Significant Clinical Benefits in Skeletal Muscle Function in Non-Ambulant Duchenne Muscular Dystrophy Patients Treated with CAP-1002 in HOPE-2 Open Label Extension Study
-Met Primary Endpoint of Performance of the Upper Limb PUL 2.0 (p=0.02)- -Results Suggest Disease Modification in DMD and Long-term Safety of CAP-1002- -Results were Presented at Late Breaking Session at PPMD’s Annual Conference on Saturday June 25, 2022- ...
GlobeNewswire · 06/27 11:00
Capricor Therapeutics Says CAP-1002 Study Data Shows 'Statistically Significant Improvements' to Treat Muscular Dystrophy
MT Newswires · 06/27 08:03
BRIEF-Capricor Therapeutics To Present One-Year Efficacy Results From Its Ongoing Hope-2 Open Label Extension Study At 2022 Parent Project Muscular Dystrophy Annual Conference
reuters.com · 06/17 13:01
Capricor Therapeutics to Present One-Year Efficacy Results from its Ongoing HOPE-2 Open Label Extension Study at 2022 Parent Project Muscular Dystrophy Annual Conference
Results to be Presented in Late-Breaking SessionSAN DIEGO, June 17, 2022 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment an...
GlobeNewswire · 06/17 13:00
Capricor Therapeutics to Present at the H.C. Wainwright Global Investment Conference
SAN DIEGO, May 18, 2022 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, ann...
GlobeNewswire · 05/18 13:00
-- Earnings Flash (CAPR) CAPRICOR THERAPEUTICS Reports Q1 Loss $-0.32
MT Newswires · 05/10 16:09
More
No Data
Learn about the latest financial forecast of CAPR. Analyze the recent business situations of Capricor Therapeutics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average CAPR stock price target is 15.00 with a high estimate of 18.00 and a low estimate of 12.00.
High18.00
Average15.00
Low12.00
Current 3.820
EPS
Actual
Estimate
-0.26-0.19-0.13-0.06
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 42
Institutional Holdings: 2.62M
% Owned: 10.77%
Shares Outstanding: 24.32M
TypeInstitutionsShares
Increased
9
156.17K
New
7
253.71K
Decreased
6
114.71K
Sold Out
3
24.17K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.67%
Pharmaceuticals & Medical Research
+0.63%
Key Executives
Chairman/Executive Director/Director
Frank Litvack
President/Chief Executive Officer/Director
Linda Marban
Chief Financial Officer/Chief Accounting Officer
Anthony Bergmann
Executive Vice President/General Counsel
Karen Krasney
Independent Director
Earl Collier
Independent Director
George Dunbar
Independent Director
Karimah Es Sabar
Independent Director
Louis Manzo
Independent Director
David Musket
No Data
No Data
About CAPR
Capricor Therapeutics, Inc. is a biotechnology company that is focused on developing transformative cell and exosome-based therapeutics and vaccines for treating and preventing a broad spectrum of diseases. The Company consists of cell therapy program, including CAP-1002 for Duchenne Muscular Dystrophy program and CAP-1002 with CAP-1002 for coronavirus (COVID-19). The Company’s lead candidate, CAP-1002, is an allogeneic cardiac-derived cell therapy. CAP-1002 is in clinical development for treating Duchenne muscular dystrophy and the cytokine storm associated with COVID-19. Capricor is also developing its exosome technology therapeutic platform. The Company is focused on developing exosomes capable of delivering nucleic acids, including messenger RNA (mRNA) as well as proteins, to treat or prevent a range of diseases. CAP-1002 cell therapy programs initiated Pivotal Phase III, HOPE-3.

Webull offers kinds of Capricor Therapeutics Inc stock information, including NASDAQ:CAPR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CAPR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CAPR stock methods without spending real money on the virtual paper trading platform.